In order to meet our objective to promote leukodystrophy medical research we work collaboratively with a variety of stakeholders with an interest in leukodystrophy, including pharmaceutical companies and healthcare industries that make a profit.
Read our policy on Working with Industry here.
As part of this policy we are committed to:


For further details of our income and expenditure please see our annual accounts for the financial year ending 30 June 2025: Alex TLC annual accounts
The table below outlines the individual companies and amounts received for the last two financial years to 30 June 2024 and 30 June 2025:
| Company | 2024/25 | 2023/24 |
| Minoryx | 36,900.00 | |
| Ionis | 17,000.00 | 10,000.00 |
| Orchard | 10,550.00 | |
| Vigil | 13,700.00 | 10,000.00 |
| BridgeBio | 18,232.40 | |
| Forge Biologics | 1,988.00 | |
| Neuraxpharm | 5,400.00 | |
| SynaptixBio Ltd | 1,509.52 | |
| Swanbio Therapeutics | 5,000.00 | |
| TOTAL | 105,279.92 | 25,000.00 |